{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:10:43Z","timestamp":1779145843251,"version":"3.51.4"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1055\/a-2679-0003","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:35:21Z","timestamp":1779143721000},"page":"554-561","source":"Crossref","is-referenced-by-count":0,"title":["Neues zur Therapie der Gro\u00dfgef\u00e4\u00dfvaskulitiden"],"prefix":"10.1055","volume":"151","author":[{"given":"Nadine","family":"Bochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00393-020-00893-1","article-title":"S2k-Leitlinie \u201eManagement der Gro\u00dfgef\u00e4\u00dfvaskulitiden\u201c","volume":"79","author":"S Schirmer","year":"2020","journal-title":"Z Rheumatol"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"B Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00393-024-01532-9","article-title":"Recommendations for defining giant cell arteritis fast-track clinics. English version. Empfehlungen zur Definition von Riesenzellarteriitis-Fast-Track-Kliniken","volume":"83","author":"WA Schmidt","year":"2024","journal-title":"Z Rheumatol"},{"issue":"06","key":"ref4","doi-asserted-by":"publisher","first-page":"e16665","DOI":"10.1016\/j.heliyon.2023.e16665","article-title":"Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab \u2013 An attention may be required","volume":"9","author":"M Berman","year":"2023","journal-title":"Heliyon"},{"issue":"04","key":"ref5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"JH Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"ref6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis","volume":"392","author":"D Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152351","article-title":"Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study","volume":"64","author":"F Muratore","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"05","key":"ref8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"JH Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"09","key":"ref9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"S Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study","volume":"59","author":"A Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"09","key":"ref11","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"L Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"01","key":"ref12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/rheumatology\/kead21","article-title":"Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study","volume":"63","author":"F Muratore","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"ref13","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","article-title":"Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study","volume":"5","author":"S Unizony","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13063-024-07905-4","article-title":"The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study","volume":"25","author":"L Kreis","year":"2024","journal-title":"Trials"},{"issue":"04","key":"ref17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ero.2025.10.006","article-title":"Patient perspectives on glucocorticoid-associated complications and sequelae in ANCA-associated vasculitis","volume":"1","author":"PJ Scherbacher","year":"2025","journal-title":"EULAR Rheumatology Open"},{"issue":"05","key":"ref18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"MC Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref19","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"N Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"ref20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.ard.2025.07.018","article-title":"Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis","volume":"84","author":"X Sun","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"03","key":"ref21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Y Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"09","key":"ref22","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Y Nakaoka","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"03","key":"ref23","doi-asserted-by":"publisher","first-page":"103275","DOI":"10.1016\/j.autrev.2023.103275","article-title":"The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis","volume":"22","author":"DP Misra","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study","volume":"55","author":"J Wang","year":"2022","journal-title":"Semin Arthritis Rheum"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2679-0003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:35:27Z","timestamp":1779143727000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2679-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,5,18]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2679-0003","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}